Researchers estimate that as many as 2.1 million patients with mild cognitive impairment could develop Alzheimer's dementia over a two - decade period while waiting for
evaluation and treatment resources after approval of an Alzheimer's disease - modifying
therapy by the federal
Food and Drug Administration.